Reduction in pulmonary fibrosis in vivo by halofuginone.

@article{Nagler1996ReductionIP,
  title={Reduction in pulmonary fibrosis in vivo by halofuginone.},
  author={Arnon Nagler and N Firman and Regina Feferman and S. Cotev and Marc Pines and Shmuel Shoshan},
  journal={American journal of respiratory and critical care medicine},
  year={1996},
  volume={154 4 Pt 1},
  pages={1082-6}
}
Pulmonary fibrosis is a disorder causing a high mortality rate for which therapeutic options are limited. Therefore, the effect of halofuginone, a novel inhibitor of collagen type I synthesis, on bleomycin-induced pulmonary fibrosis was studied in rats. Pulmonary fibrosis was induced by intraperitoneal injections of bleomycin for seven consecutive days, and halofuginone was administered intraperitoneally every second day during the entire experimental period of 42 d. Collagen determination in… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…